study showing rapid and effective virucidal activity of PVP-I
against SARS-CoV-2. All four products tested [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved C 99.99% virucidal activity against SARS-CoV-2, corresponding to C 4 log10 reduction of virus titre, within 30s of contact.
Anderson et al., 7/8/2020, peer-reviewed, 8 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.